Tag Archives: teplizumab

Efforts to prevent or delay type 1 diabetes have traditionally focused on the autoimmune attack that destroys insulin-producing beta cells. However, emerging research suggests metabolic stress may also influence how quickly vulnerable people progress to clinical disease. A 2026 TrialNet analysis found that autoantibody-positive people with overweight or obesity who …

Receiving a diagnosis of type 1 diabetes can feel overwhelming. Yet for many adults, the weeks or months that follow bring an unexpected twist. Blood glucose levels often become easier to control, insulin needs decrease, and some people wonder if their diabetes is actually improving. This temporary period is known …

For decades, treatment after a type 1 diabetes diagnosis focused almost entirely on insulin replacement and blood glucose management. While advances in technology have improved care, clinicians have had few ways to address the autoimmune process driving beta-cell loss. That is beginning to change. With the FDA’s expansion of teplizumab-mzwv …

As population-based screening for type 1 diabetes (T1D) becomes more common, clinicians increasingly encounter positive islet autoantibody results in children and adults who have no symptoms. However, not all positive screening results carry the same clinical significance. A single positive autoantibody may indicate elevated risk, yet the specific antibody detected …

Can we actually prevent type 1 diabetes before symptoms appear? Increasingly, the answer is yes. As research evolves, clinicians now have stronger tools to identify at-risk children earlier and delay disease progression. This shift is especially important because type 1 diabetes often develops silently before diagnosis. Therefore, early screening and …